CJMB

The Company Deepened its Government Relationships at Both State and Federal Levels, Particularly to Support Onshoring Initiatives, While Reinforcing the Strength and Stability of Core Emergency Preparedness Operations Built Momentum Across Several Growth Initiatives with Healthcare and Food Manufacturing Partners SPRING BRANCH, Texas, March 31, 2026 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced its financial results for the full year ended December 31, 2025 and is providing shareholders with a business update. “Throughout 2025 and into the new year, while our emergency preparedness business has remained the core to our operations there are several critical initiatives Callan JMB is actively pursuing with significant growth potential,” commented Wayne Williams, CEO, Chairman & Founder of Callan JMB. “Our long history and established relationships across both the state and federal levels continue to be a driver for us as potential partners seek out our knowledge and expertise. While we are focused on maintaining exceptional service levels in emergency preparedness, we are also expanding our pharmaceutical logistics and specialty distribution operations, as well as advancing U.S. onshoring initiatives. Callan JMB operates at the rigorous quality standards required for pharmaceutical distribution and our recent partnership with Attune represents a meaningful acknowledgement of our leadership in this space.” “As we look ahead into the remainder of 2026, we are focused on strengthening our core infrastructure, scaling our readiness capabilities, and advancing our strategic growth initiatives in high velocity sectors such as healthcare and food logistics. We are committed to long-term shareholder value creation by building a resilient, mission-driven organization positioned at the center of critical healthcare and national preparedness supply chains,” concluded Mr. Williams. Business Highlights to Date: Signed a manufacturing oversight, federal deployment, and commercialization agreement of multi-asset therapeutic pipeline with Biostax Corp d/b/a Attune Biotech Inc. (“Attune”), a clinical-stage biopharmaceutical company with a diversified therapeutic pipeline, to serve as independent third-party overseer of Attune 's manufacturing, quality assurance and control, and deployment operations for Attune’s pipeline of multiple clinical and commercial-stage assets whose focus is on addressing significant unmet medical needs. Advanced multiple growth initiatives with global healthcare manufacturing leaders. Established a joint venture with Revival Health, to integrate logistics, shipping systems, bioservices, and data infrastructure to support Revival Health’s imports and U.S.-based manufacturing. Launched Callan JMB Services (India) Private Limited with planned temperature-controlled warehouse in Pune, Maharashtra for pharmaceutical storage and distribution. Secured an agreement with Walker's Pharmaceuticals Ltd. and working with additional Indian companies to facilitate U.S. market entry and manufacturing plant establishment. Entered a preliminary agreement with the maker of an oral drug delivery system to install its innovative manufacturing equipment in Callan JMB’s cGMP facility in Texas. Strengthened core emergency preparedness operations, further deepening both state and federal relationships. Extended emergency preparedness contract with the City of Chicago through June 2026 with $1.5 million funding increase, bringing total contract value to $9.1 million. Awarded a second five-year contract by the Oregon Health Authority (OHA) for medical emergency preparedness and response services. Appointed former Assistant Commissioner of the Chicago Department of Public Health, Christopher Shields, as Senior Vice President, Emergency Preparedness & Response/Government Affairs. Supported Texas and New Mexico in the response to measles outbreak in each state by redistributing doses of the MMR II vaccine from Chicago to their respective states. Announced a new comprehensive lease program for vaccine management that enables government agencies and private organizations to provide crucial immunizations without the economic burden of purchasing the necessary equipment outright. Successful administration of immunizations across 44 Tennessee counties through its partnership with Health Hero Tennessee out of a dedicated operations center set up by Callan JMB. Entered the food sampling sector by expanding the Company’s reclamation operations. Upgraded the proprietary Sentry Monitoring System, transitioning from Java to HTML5 to enable healthcare facilities and emergency management agencies to monitor temperature-sensitive pharmaceutical storage from any web-enabled device without downloading additional software. Financial Highlights for the Full Year Ended December 31, 2025: Revenues for the twelve months ended December 31, 2025, was $5.7 million compared to $6.6 million for the twelve months ended December 31, 2024. The decrease in revenue was due to the decrease in demand for our emergency preparedness services by certain states and local governments. Cost of revenues for the twelve months ended December 31, 2025, was $3.6 million compared to $4 million for the twelve months ended December 31, 2024. The decrease in cost of revenue was primarily attributed to a decrease in revenue. Gross profit for the twelve months ended December 31, 2025, was $2.1 million compared to $2.6 million for the twelve months ended December 31, 2024. SG&A expenses for the twelve months ended December 31, 2025, were $8.6 million compared to $4.8 million for the twelve months ended December 31, 2024. The increase was primarily driven by increases in professional fees to support the Company’s initial public offering and becoming a public entity, as well as increases in information technology support costs. Loss from operations for the twelve months ended December 31, 2025, was $7.0 million compared to a loss of $2.3 million for the twelve months ended December 31, 2024. Cash and cash equivalents for the period ended December 31, 2025, were $2.1 million. About Callan JMB Inc. Callan JMB Inc. is an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services to secure medical materials and protect patients and communities with compliant, safe, and effective medicines. Our combined expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance and emergency preparedness is unparalleled in the industry. We offer a gold standard in client experience with customizable interfaces, next-level reliability in shipping and environmental sustainability in our specialty packaging. Forward-Looking Statement This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Registration Statement Under the Securities Act of 1933 on Form S-1, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/. Investor Contacts: Valter Pinto, Managing Director KCSA Strategic Communications [email protected] 212.896.1254 CALLAN JMB INC. (Formerly known as Coldchain Technology Services, LLC) CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2025 and 2024 The accompanying notes are an integral part of these consolidated financial statements. CALLAN JMB INC. (Formerly known as Coldchain Technology Services, LLC) CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED DECEMBER 31, 2025 and 2024 The accompanying notes are an integral part of these consolidated financial statements. CALLAN JMB INC. (Formerly known as Coldchain Technology Services, LLC) CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2025 and 2024 The accompanying notes are an integral part of these consolidated financial statements.

Expanded the Company’s compliance-driven logistics platform into the food sampling industry Entered agreement to install oral drug delivery equipment at Texas facility Established a subsidiary in India and advanced plans for a temperature-controlled pharmaceutical storage and distribution warehouse Extended the Company’s long-term contract with the City of Chicago through June 2026, including an increase in funding Upgraded Sentry Monitoring System Technology with Sentry 4 for Mobile Temperature Monitoring SPRING BRANCH, Texas, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced its financial results for the third quarter ended September 30, 2025, and is providing a business update. "Callan JMB continues to execute with excellence across our core business lines, while also leveraging our key competencies to expand into target growth areas," commented Wayne Williams, CEO, Chairman & Founder of Callan JMB. "We recently launched into the food sampling sector, as a natural extension of our core capabilities and part of our multi-variant strategic growth initiatives. We have also made progress to support the onshoring of logistics operations to the U.S. in the future, particularly for international companies operating in the pharmaceutical space. This month, we entered a preliminary agreement with a maker of an innovative drug delivery system to install its manufacturing equipment in our cGMP facility in Texas, while we negotiate further operational agreements. In July, we formed Callan JMB Services (India) Private Limited, with a planned temperature-controlled warehouse for storage and distribution of pharmaceuticals at all temperature ranges." "Our emergency preparedness business continues to perform well, with the City of Chicago extending our contract through June 2026 with an additional $1.5 million in funding, bringing the total contract value to $9.1 million and reinforcing our eight-year partnership. Finally, we enhanced our technology platform by upgrading our proprietary Sentry Monitoring System to version 4.0, transitioning from Java to HTML5 to provide healthcare facilities and emergency management agencies with seamless, device-agnostic access to critical temperature monitoring capabilities. These advancements reflect our commitment to delivering innovative solutions that meet evolving customer needs. As we close out 2025, we are focused on driving sustainable growth across our pharmaceutical logistics, emergency preparedness, and specialty distribution operations while pursuing strategic opportunities in complementary high-growth markets that build on our established skill set,” concluded Mr. Williams. Business Highlights to Date: Post quarter-end, expanded reclamation operations into food sampling sector to advance the Company’s multi-variant strategic growth initiative and extend its compliance-driven logistics platform into an adjacent, high-growth market. In November, entered a preliminary agreement with the maker of an oral drug delivery system to install its innovative manufacturing equipment in Callan JMB’s cGMP facility in Texas, while the two companies negotiate operational agreements. This agreement is the latest step in several related initiatives that the Company is planning with global manufacturing leaders in the healthcare industry, including Revival Health. Launched Callan JMB Services (India) Private Limited with planned temperature-controlled warehouse in Pune, Maharashtra for pharmaceutical storage and distribution, already securing an agreement with Walker's Pharmaceuticals Ltd. and working with additional Indian companies to facilitate U.S. market entry and manufacturing plant establishment. Extended the Company’s emergency preparedness contract with the City of Chicago extended Callan JMB's through June 2026 with $1.5 million funding increase, bringing total contract value to $9.1 million and extending the seven-year partnership for continued management and distribution of health preparedness supplies. In October, upgraded the proprietary Sentry Monitoring System to version 4.0, transitioning from Java to HTML5 to enable healthcare facilities and emergency management agencies to monitor temperature-sensitive pharmaceutical storage from any web-enabled device without downloading additional software. Financial Highlights for the Three- and Nine-Month Periods Ended September 30, 2025: Revenues for the three months and nine months ended September 30, 2025 were $1.4 million and $4.6 million, respectively. The decrease in year-over-year revenue was due to the seasonal decline in the demand for emergency preparedness services by certain states and local governments during the third quarter. Cost of revenues for the three months and nine months ended September 30, 2025 were $1.0 million and $2.8 million, respectively. The decrease in cost revenue is due to a decrease in labor and freight forwarding. Gross profit for the three months and nine months ended September 30, 2025 were $0.5 million and $1.8 million, respectively. SG&A expenses for the three months and nine months ended September 30, 2025 were $2.4 million and $6.3 million. The increase year-over-year was primarily driven by an increase in consulting, professional fees and marketing expenses related to the Company now being a public entity. Loss from operations for the three months and nine months ended September 30, 2025 were ($1.9) million and ($4.5) million, respectively. Cash and cash equivalents for the period ended September 30, 2025 were $2.8 million. About Callan JMB Inc. Callan JMB Inc. is an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services to secure medical materials and protect patients and communities with compliant, safe, and effective medicines. Our combined expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance and emergency preparedness is unparalleled in the industry. We offer a gold standard in client experience with customizable interfaces, next-level reliability in shipping and environmental sustainability in our specialty packaging. Forward-Looking Statement This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Registration Statement Under the Securities Act of 1933 on Form S-1, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/. Investor Contacts: Valter Pinto, Managing Director KCSA Strategic Communications [email protected] 212.896.1254 CALLAN JMB INC. (Formerly known as Coldchain Technology Services, LLC) CONDENSED CONSOLIDATED BALANCE SHEETS CALLAN JMB INC. (Formerly known as Coldchain Technology Services, LLC) CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) CALLAN JMB INC. (Formerly known as Coldchain Technology Services, LLC) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Formed a strategic partnership with Revival Health Inc. (“Revival”) to deliver fully integrated supply chain services and infrastructure to support both the importation and onshore manufacturing of health, wellness, and longevity products Launched subsidiary in India and progressed to establish temperature-controlled warehouse for storage and distribution of pharmaceuticals at all temperature ranges Extended long-term contract with City of Chicago and received increase in funding Appointed Christopher Shields, former Assistant Commissioner of the Chicago Department of Public Health, as Senior Vice President, Emergency Preparedness & Response/Government Affairs Supported Texas and New Mexico with measles outbreak response through redistribution of MMR II vaccines SPRING BRANCH, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced its financial results for the second quarter ended June 30, 2025 and provided a business update. "Callan JMB continues to solidify its position as a leading provider of specialized logistics solutions within high-growth opportunity markets, demonstrating our operational excellence through several key recent achievements," commented Wayne Williams, CEO, Chairman & Founder of Callan JMB. "We were proud to form a strategic partnership with Revival to develop a broad supply platform for healthcare products, changing the way they are made available across the country. In July, we further expanded our market for global pharmaceutical cold chain logistics and clinical trial support by launching a subsidiary in India to establish temperature-controlled warehouses for storage and distribution. This international expansion positions us to import critical tissue samples for clinical trials and active pharmaceutical ingredients, helping address U.S. drug shortages.” “Furthermore, we recently extended our emergency preparedness contract with the City of Chicago through June 2026 with $1.5 million in additional funding, bringing total contract value to $9.1 million. During the quarter, the Company appointed Christopher Shields as Senior Vice President, Emergency Preparedness & Response/Government Affairs, to grow our emergency preparedness & response operations into new U.S. cities, states, and other countries. We also successfully redistributed over 1,300 MMR II vaccine doses during the measles outbreak response with zero waste, showcasing our technological efficiency and sustainability credentials. Looking ahead, we remain focused on capitalizing on expansion opportunities within fast-growing industries, particularly GLP-1 pharmaceutical distribution, specialty compounding pharmacy logistics, and premium food packaging solutions. Callan JMB remains well-placed for sustained growth and market leadership through 2025," added Mr. Williams. Business Highlights: Formed strategic partnership with Revival to create integrated supply chain infrastructure for health, wellness, and longevity products, combining cold chain logistics expertise with consumer health innovation for scalable distribution solutions. Post quarter end launched Callan JMB Services (India) Private Limited with planned temperature-controlled warehouse in Pune, Maharashtra for pharmaceutical storage and distribution, already securing an agreement with Walker's Pharmaceuticals Ltd. and working with additional Indian companies to facilitate U.S. market entry and manufacturing plant establishment. In July, the City of Chicago extended Callan JMB's emergency preparedness contract through June 2026 with $1.5 million funding increase, bringing total contract value to $9.1 million and extending the seven-year partnership for continued management and distribution of health preparedness supplies. Appointed Christopher Shields, former Assistant Commissioner of the Chicago Department of Public Health, as Senior Vice President, Emergency Preparedness & Response/Government Affairs. Successfully redistributed over 1,300 MMR II vaccine doses from Chicago to Texas and New Mexico during measles outbreak response using specialized cold chain reusable shippers with zero waste, demonstrating emergency response capabilities and sustainable logistics solutions. Financial Highlights for the Year Ended June 30, 2025: Revenues for the three months and six months ended June 30, 2025 were $1.7 million and $3.1 million, respectively. The decrease year-over-year in revenue was due to the decline in demand for our emergency preparedness services by certain states and local governments. Cost of revenues for the three months and six months ended June 30, 2025 were $1.0 million and 1.9 million, respectively. The decrease year-over-year in cost of revenue is in line with the decrease in revenues. Gross profit for the three months and six months ended June 30, 2025 were $0.6 million and 1.3 million, respectively. SG&A expenses for the three months and six months ended June 30, 2025 were $2.0 million and $3.9 million. The increase year-over-year was primarily driven by an increase in consulting, professional fees and marketing expenses related to the Company now being a public entity and adding the Company’s CEO to payroll for the first time, along with other senior staff hires to support future growth. Loss from operations for the three months and six months ended June 30, 2025 were $1.4 million and $2.6 million, respectively. Cash and cash equivalents for the period ended June 30, 2025 were $4.2 million. Subsequent to quarter end, the Company entered into an equity line of credit agreement with an investor for the right to sell up to $25 million of shares of the Company’s common stock. About Callan JMB Inc. Callan JMB Inc. is an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services to secure medical materials and protect patients and communities with compliant, safe, and effective medicines. Our combined expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance and emergency preparedness is unparalleled in the industry. We offer a gold standard in client experience with customizable interfaces, next-level reliability in shipping and environmental sustainability in our specialty packaging. Forward-Looking Statement This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Registration Statement Under the Securities Act of 1933 on Form S-1, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/. Investor Contacts: Valter Pinto, Managing Director KCSA Strategic Communications [email protected] 212.896.1254 CALLAN JMB INC. (Formerly known as Coldchain Technology Services, LLC) CONDENSED CONSOLIDATED BALANCE SHEETS CALLAN JMB INC. (Formerly known as Coldchain Technology Services, LLC) CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) CALLAN JMB INC. (Formerly known as Coldchain Technology Services, LLC) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Completed Initial Public Offering (IPO) on February 6, 2025, at $4.00 per Share for Gross Proceeds of Approximately $5.7 Million, Including Partial Exercise of Over-Allotment Option SPRING BRANCH, Texas, May 15, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced its financial results for the first quarter ended March 31, 2025 and is providing a business update. "Callan JMB is establishing itself as the premier provider of advanced logistics and value-added fulfillment services across high-growth sectors," stated Wayne Williams, CEO & Chairman of Callan JMB. "By leveraging our core competitive strengths, we are strategically scaling our proven business model into emerging markets where our expertise creates significant value. Our innovative solutions are disrupting traditional approaches by delivering customized configurations that precisely meet our client’s needs. We are actively pursuing growth opportunities in rapidly expanding markets, including GLP-1 pharmaceutical transportation, specialized compounding pharmacy logistics, and premium food packaging services. We are already engaged in promising discussions with potential partners in these sectors and look forward to sharing developments in the near future." "Simultaneously, we are executing a national expansion of our emergency preparedness and response operations. We have identified substantial growth potential in untapped metropolitan areas and states, and our recent appointment of Christopher Shields as Senior Vice President of Emergency Preparedness & Response/Government Affairs will accelerate our geographic expansion. Callan JMB is well positioned for sustained growth and market leadership as we progress through 2025," concluded Mr. Williams. Business Highlights to Date: On February 6, 2025, completed IPO at $4.00 per share with gross proceeds of approximately $5.7 million, including partial exercise of over-allotment. Announced the appointment of former Assistant Commissioner of the Chicago Department of Public Health, Christopher Shields, as Senior Vice President, Emergency Preparedness & Response/Government Affairs. Requested by the State of Texas Department of Health and Human Services to be on standby in readiness to assist with the response to the recent outbreak of measles. Renewed the Company’s arrangement with the Texas Department of State Health Services (DSHS) as the state transitions from heightened readiness to a sustainment phase following the COVID-19 pandemic. Callan JMB will provide ongoing updates on facility and personnel readiness while consulting with the DSHS to maintain alignment for potential future elevated status responses as part of its contract with the agency. Granted a second five-year contract by the Oregon Health Authority for medical emergency preparedness and response services. The new contract includes Callan JMB’s services for storing and managing a broad inventory of medical countermeasures to meet all new threat assessments and event response missions in the State of Oregon. Commenced a comprehensive lease program for vaccine management, enabling government agencies and private organizations to provide crucial immunizations without the financial burden of purchasing equipment outright. Supported Health Hero Tennessee with its voluntary, statewide immunization initiative. Financial Highlights for the Year Ended March 31, 2025: Revenue for the first quarter of 2025 of $1.45 million. The decrease in revenue this quarter was due to the decline in demand for our emergency preparedness services by certain states and local governments. Cost of revenue for the first quarter of 2025 of $0.8 million. Gross profit and gross profit margin for the first quarter of 2025 totaled $0.6 million and 42.5%, respectively. SG&A expenses for the first quarter of 2025 were $1.9 million. The increase year-over-year was primarily driven by an increase in consulting and professional fees related to the Company’s IPO and adding the Company’s CEO to payroll for the first time, along with other senior staff hires to support future growth. Operating income (loss) for the first quarter of 2025 was ($1.2) million. Net income (loss) for the first quarter of 2025 was ($1.2) million. About Callan JMB Inc. Callan JMB Inc. is an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services to secure medical materials and protect patients and communities with compliant, safe, and effective medicines. Our combined expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance and emergency preparedness is unparalleled in the industry. We offer a gold standard in client experience with customizable interfaces, next-level reliability in shipping and environmental sustainability in our specialty packaging. Forward-Looking Statement This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Registration Statement Under the Securities Act of 1933 on Form S-1, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/. Investor Contacts: Valter Pinto, Managing DirectorKCSA Strategic [email protected] CALLAN JMB INC.(Formerly known as Coldchain Technology Services, LLC)CONDENSED CONSOLIDATED BALANCE SHEETS as ofMarch 31, 2025 (Unaudited) AND DECEMBER 31, 2024 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSFOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024 (Unaudited) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024 (Unaudited)

Successfully Closed IPO on February 6, 2025, at $4.00 per Share for Gross Proceeds of Approximately $5.7 Million, Including Partial Exercise of Over-Allotment Option SPRING BRANCH, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced its financial results for the full year ended December 31, 2024, and provided a business update. "2024 was a pivotal year for Callan JMB as we continued to deliver exceptional service to our diverse client base while also preparing for our IPO," said Wayne Williams, CEO & Chairman of Callan JMB. "Closing our IPO in February 2025 was an exciting milestone and a testament to our team's hard work. For years, we have been a trusted partner to both public and private sector customers, consistently delivering excellence and reliability in emergency preparedness, logistics, and fulfillment." "Looking ahead, we remain focused on scaling our existing business and expanding into new high-growth market opportunities. We are leveraging our core competitive strengths, including our proven success in thermal shipping, to capitalize on opportunities in the healthcare and food and beverage industries. Our leading end-to-end monitoring technology helps to ensure the quality and safety of shipments, giving customers confidence that their packages will arrive in pristine condition, and safeguarding patient health and consumer satisfaction. This competitive edge positions us well as we expand into GLP-1 transportation, compounding pharmacies, and high-end food packaging," concluded Mr. Williams. Business Highlights to Date: Successfully closed IPO on February 6, 2025, at $4.00 per share with gross proceeds of approximately $5.7 million including partial exercise of over-allotment. Received request from the State of Texas Department of Health and Human Services to be on standby in readiness to assist with the response to the recent outbreak of measles. Extended the Company’s arrangement with the Texas Department of State Health Services (DSHS) as the state transitions from heightened readiness to a sustainment phase following the COVID-19 pandemic. Callan will provide ongoing updates on facility and personnel readiness while consulting with the DSHS to maintain alignment for potential future elevated status responses as part of its contract with the agency. Awarded a second five-year contract by the Oregon Health Authority for medical emergency preparedness and response services. The new contract involves Callan JMB’s services for storing and managing a broad inventory of medical countermeasures to meet all new threat assessments and event response missions in the State of Oregon. Launched a comprehensive lease program for vaccine management, enabling government agencies and private organizations to provide crucial immunizations without the financial burden of purchasing equipment outright. Supported Health Hero Tennessee’s statewide voluntary immunization initiative. Joined Complete Group Services, the first-ever group service organization developed to support compounding and manufacturing companies. Together with the other members, Callan will offer support and services to the compounding and manufacturing communities and provide access to resources targeted at helping the members grow their businesses and increase profitability. Supported long-time client, the Chicago Department of Public Health, in successfully containing a measles outbreak through a comprehensive vaccine management plan. Financial Highlights for the Year Ended December 31, 2024: Revenue for 2024 totaled $6.6 million. Revenue by distribution channel for 2024 was $3.8 million for emergency response and $2.8 million for specialty packaging. Cost of revenue for 2024 totaled $4 million. Gross profit and gross profit margin for 2024 totaled $2.6 million and was 39.1%, respectively. Operating income (loss) for 2024 was ($2.3) million. Net income (loss) for 2024 was ($2.3) million. Revenue year-over-year was impacted by a reduction in related emergency preparedness services after the COVID-19 pandemic and a customer that temporarily suspended ordering in 2024. The Company anticipates continued business from this customer in the future. About Callan JMB Inc. Callan JMB Inc. is an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services to secure medical materials and protect patients and communities with compliant, safe, and effective medicines. Our combined expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance and emergency preparedness is unparalleled in the industry. We offer a gold standard in client experience with customizable interfaces, next-level reliability in shipping and environmental sustainability in our specialty packaging. Forward-Looking Statement This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Registration Statement Under the Securities Act of 1933 on Form S-1, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/. Investor Contacts:Valter Pinto, Managing DirectorKCSA Strategic [email protected]